Related Experiment Video
Updated: Jun 9, 2026

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
The economic burden
1Temple University School of Pharmacy, 3307 North Broad Street, Philadelphia, Pennsylvania 19140, USA. albert.wertheimer@temple.edu
Chemo brain, a significant medical issue, costs the US nearly $300 million annually in direct and indirect expenses. Developing safer chemotherapy agents could substantially reduce these economic burdens.
Area of Science:
- Oncology
- Neuroscience
- Health Economics
Background:
- Chemo brain (cognitive dysfunction) is a prevalent and persistent side effect of chemotherapy.
- This condition imposes substantial direct and indirect economic costs, primarily due to lost productivity.
Purpose of the Study:
- To quantify the annual economic burden of chemo brain in the United States.
- To highlight the need for developing safer chemotherapeutic agents to mitigate these costs.
Main Methods:
- Analysis of direct and indirect expenses associated with chemo brain.
- Estimation of productivity losses attributed to the condition.
Main Results:
- Chemo brain incurs nearly $300 million in annual direct and indirect costs in the US.
- Lost productivity contributes an additional $250 million yearly to the overall economic impact.
Conclusions:
- Chemo brain represents a significant economic burden that could be largely avoided.
- There is a critical need for biomedical scientists to develop safer chemotherapeutic agents.
Related Concept Videos
Cognitive Dissonance
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Social Traps
Fundamental Attribution Error
Energy Budgets and Reproductive Strategies
Social Exchange Theory